LENZ Therapeutics, Inc. quarterly report, Q2 FY2021

Issuer and reporting period

Important issuer mismatch: The supplied filing is Graphite Bio, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2021, not a filing for LENZ Therapeutics, Inc. The summary below covers Graphite Bio.

Business context and financial results

Graphite Bio was a clinical-stage gene-editing company with no product sales or product revenue. Its lead candidate, GPH101, targets sickle cell disease. The filing reports three- and six-month results through June 30, 2021, compared with the same 2020 periods; balance-sheet figures compare June 30, 2021 with December 31, 2020. Dollar amounts below are in millions unless noted.

Margins are not meaningful because the company had no revenue. At June 30, cash and cash equivalents were $382.0 million, restricted cash was $0.1 million, current liabilities were $7.9 million, and total liabilities were $7.9 million. The balance sheet showed no outstanding debt line item. Accumulated deficit was $107.8 million.

Changes versus the prior comparable period

Q2 net loss widened from $1.3 million in 2020 to $17.5 million in 2021; six-month net loss increased from $1.5 million to $37.2 million. R&D expense rose to $12.7 million for Q2 from $0.4 million, and to $18.0 million for six months from $0.4 million. Management attributed the increases chiefly to clinical-trial and contract-manufacturing activity, higher personnel costs, and a $3.0 million IDT license charge. G&A expense also increased, including higher employee and professional-service costs.

Six-month operating cash use increased from $1.0 million in 2020 to $21.8 million in 2021. Financing provided $385.3 million, principally from preferred-stock financing and the IPO. The IPO generated $219.5 million of net proceeds recognized in June; the underwriters’ additional-share option closed in July. Total net IPO proceeds for June and July were reported as approximately $251.4 million.

Outlook, risks, and unusual items

• Management expected June 30 cash and restricted cash to fund the current operating plan for at least 12 months. A risk-factor disclosure, including the July IPO proceeds, said funds were expected to support operations into 2024. These are management estimates, not guaranteed runway.
• The company had FDA clearance of GPH101’s IND and intended to enroll the first patient in a Phase 1/2 trial in the second half of 2021; initial proof-of-concept data were expected by the end of 2022. It also intended to file an IND for a second program by mid-2023.
• The six-month loss included a $10.3 million noncash charge from remeasuring the Series A preferred-stock tranche liability. The liability was settled when the final Series A tranche closed in February 2021.
• Before the IPO, all preferred shares converted into common stock. The IPO and related conversion substantially changed the company’s capitalization; the filing reported 55,979,002 common shares outstanding at June 30 and 58,079,002 at August 9.
• Key risks include early-stage clinical and preclinical development, potential gene-editing safety and regulatory hurdles, patent and licensing disputes, reliance on third-party and potentially single-source manufacturers, patient recruitment, and COVID-19-related disruption. Stanford’s IND filing had been delayed by the pandemic, although the company said its operations had not yet been significantly affected.
• The IDT license required a $3.0 million upfront payment, potential regulatory milestones, and low-single-digit royalties. Stanford agreements also include potential milestones, royalties, and diligence requirements. No license milestones were recorded as achieved or probable at June 30.

Important facts for investors to verify

• Confirm the issuer: this filing is for Graphite Bio, not LENZ Therapeutics.
• Check subsequent disclosures for whether GPH101’s planned Phase 1/2 enrollment and data milestones occurred on schedule.
• Reconcile the stated 12-month liquidity expectation with the risk-factor estimate of funding into 2024, including the July IPO proceeds and evolving spending plans.
• Review cash burn and the timing and scale of future clinical, manufacturing, and public-company expenses; the company expected expenses to rise substantially.
• Assess the terms, scope, diligence obligations, and intellectual-property dependencies of the Stanford and IDT licenses, along with clinical, manufacturing, and patent risks.